Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease.
DaTScan
Parkinson’s disease
motor
non-motor
sex
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
9
11
2021
medline:
28
4
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Investigation of sex-related motor and non-motor differences and biological markers in Parkinson's disease (PD) may improve precision medicine approach. To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD. We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N = 423; 65.5%male) of the Parkinson's Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscanTM uptake. Men experienced greater longitudinal decline in self-reported motor (p < 0.001) and non-motor (p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state (p = 0.010) and required higher dopaminergic medication dosages over time (p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscanTM uptake were not different by sex. Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.
Sections du résumé
BACKGROUND
Investigation of sex-related motor and non-motor differences and biological markers in Parkinson's disease (PD) may improve precision medicine approach.
OBJECTIVE
To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD.
METHODS
We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N = 423; 65.5%male) of the Parkinson's Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscanTM uptake.
RESULTS
Men experienced greater longitudinal decline in self-reported motor (p < 0.001) and non-motor (p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state (p = 0.010) and required higher dopaminergic medication dosages over time (p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscanTM uptake were not different by sex.
CONCLUSION
Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.
Identifiants
pubmed: 34744052
pii: JPD212892
doi: 10.3233/JPD-212892
pmc: PMC8842783
doi:
Substances chimiques
Biological Products
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-436Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM139776
Pays : United States
Références
Ann Neurol. 2020 Sep;88(3):574-587
pubmed: 32542885
J Neurol. 2020 Jan;267(1):57-63
pubmed: 31555978
Lancet Neurol. 2016 Apr;15(5):451-2
pubmed: 26987699
Front Neuroendocrinol. 2014 Aug;35(3):370-84
pubmed: 24607323
Mov Disord. 2013 Dec;28(14):1980-6
pubmed: 24123383
Neurobiol Aging. 2015 Apr;36(4):1757-1763
pubmed: 25697414
J Neurol Sci. 2012 Dec 15;323(1-2):33-9
pubmed: 22935408
Mov Disord. 2019 Oct;34(10):1480-1487
pubmed: 31291488
J Neurol. 2013 Nov;260(11):2849-55
pubmed: 23989344
Parkinsonism Relat Disord. 2013 Dec;19(12):1094-9
pubmed: 23931933
Exp Neurol. 2014 Sep;259:44-56
pubmed: 24681088
Parkinsonism Relat Disord. 2016 May;26:67-72
pubmed: 26952697
Nat Rev Neurol. 2020 Feb;16(2):84-96
pubmed: 31900464
Neurology. 2015 Oct 13;85(15):1276-82
pubmed: 26362285
J Neurol. 2017 Aug;264(8):1583-1607
pubmed: 28054129
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neurology. 2014 Sep 30;83(14):1253-60
pubmed: 25171928
Neurosci Biobehav Rev. 2016 Aug;67:79-88
pubmed: 26708712
Neurology. 2014 Jan 14;82(2):163-71
pubmed: 24336138
Parkinsonism Relat Disord. 2016 Jun;27:89-92
pubmed: 27066847
Parkinsonism Relat Disord. 2014 Aug;20(8):850-4
pubmed: 24842702
J Neurol. 2012 Aug;259(8):1639-47
pubmed: 22237822
Neurology. 2017 Nov 7;89(19):1959-1969
pubmed: 29030452
Arch Neurol. 2005 Apr;62(4):601-5
pubmed: 15824260
Mov Disord Clin Pract. 2017 Jan 05;4(4):529-535
pubmed: 30363416
Eur J Neurol. 2019 Feb;26(2):246-e18
pubmed: 30169897
BMC Womens Health. 2015 Oct 26;15:94
pubmed: 26503700
Mov Disord. 2021 Jan;36(1):106-117
pubmed: 33002231
Gend Med. 2011 Jun;8(3):209-17
pubmed: 21664587
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):905-6
pubmed: 17635983
Mov Disord. 2000 May;15(3):490-6
pubmed: 10830414
JAMA Neurol. 2014 Mar;71(3):291-9
pubmed: 24395393
J Neurol. 2021 May;268(5):1903-1912
pubmed: 33399968
J Parkinsons Dis. 2019;9(3):501-515
pubmed: 31282427
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Parkinsonism Relat Disord. 2010 Sep;16(8):490-7
pubmed: 20598622
Parkinsonism Relat Disord. 2018 May;50:29-36
pubmed: 29478836
J Neural Transm (Vienna). 2013 Oct;120(10):1421-4
pubmed: 23532360
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24
pubmed: 17098842
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503